each evening from Day 7 to Day 28 of each cycle. This completely relieved the cyclical cedema over an eleven-month period. Luteal phase prolactin levels were 7.7 (s.d.±2.1) ng/ml (n=12) during therapy and these values were significantly lower than the pretreatment values (P<0.05). The patient's weight fluctuated by less than 1 kg during the cycle and further investigation demonstrated that she was in fluid balance. Plasma renin levels were normal during the luteal phase of the cycle (21 and 17 ng/l/min lying, 19 and 31 ng/l/min standing). Comment 'Idiopathic' cedema is a common, but ill-defined, condition which has been recognized for more than half a century. It affects women during the reproductive phase of life and is commonly but not invariably worse in the premenstrual phase. (Minor degrees of fluid retention are generally considered to be 'physiological'.) Patients are frequently obese and emotional lability may be common (Lancet 1972) .
The possible relationship of this patient's cyclical cedema to an abnormality of prolactin secretion was considered in view of the past history of galactorrhcea and the knowledge that prolactin can cause renal retention of sodium and water (Horrobin et al. 1971 ). Most women show little change in plasma prolactin concentration between the follicular and luteal phases (Friesen & Hwang 1973) ; but in this patient it was significantly higher in the luteal than in the follicular phase. A substantial reduction of plasma prolactin levels by 2-bromo-a-ergocryptine was associated with complete relief of premenstrual fluid and electrolyte retention; this suggests that prolactin may play a part in the development of 'idiopathic cedema' in some patients, and warrants further study. The reduction in plasma renin activity to undetectable levels during the luteal phase suggested that the renin-angiotensinaldosterone mechanism played no part in the observed changes and was secondarily suppressed by some other fluid and electrolyte retaining substance. Since bromocriptine is a doparnine agonist, and dopamine can cause renal fluid and electrolyte excretion, this might account for part of its action in our patient.
The patient's initial response to lithium therapy is noteworthy. Lithium has major effects in many organs, particularly those involved with ion transport and polypeptide hormone action. It has been suggested that lithium exerts its actions by incomplete ion substitution and by interfering with cAMP processes that are regulated by polypeptide hormones (Singer & Rotenberg 1973 , Forrest et al. 1974 ). It seems likely, therefore, that lithium interferes with the renal actions of pro-lactin, and that the initial good clinical response in this patient was lost when the prolactin levels during the luteal phase rose to very high levels, thus overcoming the antagonism by lithium. C P, woman aged 46. Housewife History: January 1975: developed cough, myalgia and malaise, received oxytetracycline. Four days after onset started nausea, vomiting and diarrhoea. Three days later suffered two grand mal fits, leading to hospital admission. It was later learnt that she had been investigated for primary amenorrhoea in 1951, when small uterus, atrophic endometrium and low 17 oxosteroid excretion were disclosed. Pituitary fossa and BMR were normal. She was treated with a course of stilbcestrol. She had lived in Russia until her teens and had recently married. On examination: Skin cool, pale and fine in texture. Pubic and axillary hair absent, breasts poorly developed. Pulse 60/min, BP 130/80 mmHg. Visual fields full to confrontation, fundi normal. Transitory left pyramidal signs, tendon jerks showed slow relaxation. There was no meningism. Initial investigations: Skull X-ray normal. Chest X-ray scarred right upper zone. Hb 10.9 g/100 ml. WBC 4000 mm-3. Plasma sodium 108 mmol/l (normal 136-147), potassium 3.4 mmol/l (normal 3.8-5.2), bicarbonate 24 mmol/l (normal 20-30), urea 3.0 mmol/l (normal 2.5-6.5), cortisol 0.18 pmol/l (low), blood sugar 4.9 mmol/l (normal 3.2-10.0). Management: It was considered that longstanding hypopituitarism had been exacerbated by infection, leading to water intoxication and fits. She was given 1 litre 2N saline (NaCl 308 mmol/l) and' restricted oral fluids. Parenteral hydrocortisone therapy was given, replaced after 48 hours by oral prednisone.
On Days 6-8 of her inpatient admission she received Synacthen Depot I mg i.m. daily. After clinical improvement for seven days she became psychotic and paranoid over the next two days. She then improved considerably but remained apprehensive and uncooperative, limiting further investigations. She went home on the 18th day taking thyroxine 0.1 mg daily and prednisone 2.5 mg three times a day. Further investigations: Pituitary tomography, EEG and ECG normal. Reiter protein complement fixation text and VDRL negative. Antinuclear factor negative. Twenty-four-hour urinary LH 2 iu, FSH 1.5 iu. Karyotype: normal female. Adrenal function on Day 9 (soluble Synacthen 0.25 mg i.m.): plasma cortisol at 0 min, 1.52 tkmol/l; at 30 min, 1.56 ,umol/l; at 60 min, 1.38 ,umol/l (all grossly elevated). On Day 11 (insulin 0.1 u/kg i.v.): no rise in plasma cortisol or serum growth hormone (minimum blood sugar 0.5 mmol/l). Thyroid status: Serum T4 56 nmol/l (normal 60-150), Thyopac-4 126% (normal 95-119), free thyroxine index 0.44 (normal 0.60-1.50), serum T3 0.3 nmol/l (normal 1.2-2.8). Thyroid microsomal and thyroglobulin antibodies negative. Serum cholesterol 5.1 mmol/l (normal 4.0-7.5). TRH rest (200 ,tg i.v.): at 0 min 7.0 mu/I; at 10 min, 15.6; at 20 min, 17.0; at 40 min, 18.1; at 60 min, 29.4 mu/I. Follow up: A marked physical and mental improvement was made on thyroxine and prednisone replacement therapy. Six months later she permitted further investigations, previously refused, which disclosed: significant rise in neck uptake of 1311 following bovine TSH; a paradoxical fall in FSH and LH after LHRH (basal FSH 5.3 u/I; LH 3.6 u/I). At a later date an EMI scan of her skull was normal. Comment A number of unusual features were present in this case. The florid psychosis seemed to have a metabolic basis related to initial hypopituitarism with adrenal and thyroid insufficiency and water intoxication and then rapidly changing biochemical status with correction of hypo-osmolality and rapid rise in plasma cortisol to elevated levels. Psychosis in hypopituitarism has been previously described (Blau & Hinton 1960 ). In addition it seemed likely that there was an underlying schizoid personality.
The etiology of the pituitary failure also remains unclear. A pituitary tumour was effectively excluded radiologically and by EMI scanning. Hypothalamic dysfunction is a possibility, manifesting initially with primary amenorrhoea, yet permitting, or arising after, full skeletal development.
The TRH test showed a continued rise in plasma TSH for 60 minutes, suggesting a possible pituitary or hypothalamic disorder. In some such cases a high basal level of immunoreactive TSH has been reported (Patel & Burger 1973 , Faglia et al. 1973 . It was considered that this might reflect the secretion of biologically inactive TSH and so the samples from the TRH test were re-assayed using the sensitive cytochemical bioassay (CBA) (Mr V Petersen). The results displayed an atypical discrepancy from the radioimmunoassay (RIA) results: Primary hypothyroidism was excluded by the subnormal basal level of bioassayable TSH (Petersen et al. 1975) , by the absence of thyroid antibodies and positive thyroidal response to exogenous TSH. One previous case of biologically inactive TSH secretion has been reported (Krieger 1974) .
